AU2016209363B2 - Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat - Google Patents

Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat Download PDF

Info

Publication number
AU2016209363B2
AU2016209363B2 AU2016209363A AU2016209363A AU2016209363B2 AU 2016209363 B2 AU2016209363 B2 AU 2016209363B2 AU 2016209363 A AU2016209363 A AU 2016209363A AU 2016209363 A AU2016209363 A AU 2016209363A AU 2016209363 B2 AU2016209363 B2 AU 2016209363B2
Authority
AU
Australia
Prior art keywords
inhaler
dose
port
dry powder
fluticasone propionate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016209363A
Other languages
English (en)
Other versions
AU2016209363A1 (en
Inventor
Mukul Dalvi
Seah Kee Tee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016209363(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of AU2016209363A1 publication Critical patent/AU2016209363A1/en
Application granted granted Critical
Publication of AU2016209363B2 publication Critical patent/AU2016209363B2/en
Priority to AU2021202784A priority Critical patent/AU2021202784A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016209363A 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat Active AU2016209363B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202784A AU2021202784A1 (en) 2015-01-20 2021-05-04 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
US62/105,479 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202784A Division AU2021202784A1 (en) 2015-01-20 2021-05-04 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (2)

Publication Number Publication Date
AU2016209363A1 AU2016209363A1 (en) 2017-08-24
AU2016209363B2 true AU2016209363B2 (en) 2021-02-04

Family

ID=55443303

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016209363A Active AU2016209363B2 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat
AU2021202784A Abandoned AU2021202784A1 (en) 2015-01-20 2021-05-04 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202784A Abandoned AU2021202784A1 (en) 2015-01-20 2021-05-04 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Country Status (19)

Country Link
US (2) US9415008B2 (enExample)
EP (1) EP3247331A1 (enExample)
JP (1) JP2018503687A (enExample)
KR (1) KR20170103975A (enExample)
CN (1) CN107530357A (enExample)
AR (1) AR104771A1 (enExample)
AU (2) AU2016209363B2 (enExample)
BR (1) BR112017015353A2 (enExample)
CA (1) CA2974125A1 (enExample)
CL (1) CL2017001859A1 (enExample)
CO (1) CO2017008395A2 (enExample)
EA (1) EA201791632A1 (enExample)
HK (1) HK1245125A1 (enExample)
IL (1) IL253499A0 (enExample)
MA (1) MA41378A (enExample)
MX (2) MX383344B (enExample)
PE (1) PE20171258A1 (enExample)
TW (1) TW201628607A (enExample)
WO (1) WO2016118589A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243320A1 (en) * 2013-10-07 2016-08-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
ES2884802T3 (es) * 2016-11-18 2021-12-13 Norton Waterford Ltd Dispositivo de administración de fármacos con componentes electrónicos
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) * 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020078950A1 (en) * 2000-06-23 2002-06-27 O'leary David Reservoir pressure system for medicament inhaler
US20020088463A1 (en) * 2000-06-23 2002-07-11 Lawrence Keane De-agglomerator for breath-actuated dry powder inhaler
US20130064870A1 (en) * 2010-05-20 2013-03-14 Sun Pharma Advanced Research Company Limited Dry powder inhalation composition
WO2015054124A2 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
PL2436414T3 (pl) * 2010-05-18 2015-10-30 Ivax Pharmaceuticals Ireland Licznik dawek do inhalatorów i inhalator
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
AU2014261539A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
CN105358520B (zh) * 2013-05-03 2017-05-03 陶氏环球技术有限责任公司 平衡限制反应的方法
JP6653324B2 (ja) * 2014-10-16 2020-02-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 乾燥粉末製剤
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020078950A1 (en) * 2000-06-23 2002-06-27 O'leary David Reservoir pressure system for medicament inhaler
US20020088463A1 (en) * 2000-06-23 2002-07-11 Lawrence Keane De-agglomerator for breath-actuated dry powder inhaler
US20130064870A1 (en) * 2010-05-20 2013-03-14 Sun Pharma Advanced Research Company Limited Dry powder inhalation composition
WO2015054124A2 (en) * 2013-10-07 2015-04-16 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler

Also Published As

Publication number Publication date
HK1245125A1 (zh) 2018-08-24
US9415008B2 (en) 2016-08-16
KR20170103975A (ko) 2017-09-13
MX2017009122A (es) 2017-10-12
BR112017015353A2 (pt) 2018-01-16
US20160206559A1 (en) 2016-07-21
CA2974125A1 (en) 2016-07-28
PE20171258A1 (es) 2017-08-28
AR104771A1 (es) 2017-08-16
JP2018503687A (ja) 2018-02-08
WO2016118589A1 (en) 2016-07-28
EP3247331A1 (en) 2017-11-29
CN107530357A (zh) 2018-01-02
EA201791632A1 (ru) 2017-12-29
CL2017001859A1 (es) 2018-04-06
MX2021006751A (es) 2021-07-15
CO2017008395A2 (es) 2018-01-05
US20180015035A1 (en) 2018-01-18
AU2021202784A1 (en) 2021-05-27
MX383344B (es) 2025-03-13
IL253499A0 (en) 2017-09-28
MA41378A (fr) 2017-11-28
TW201628607A (zh) 2016-08-16
AU2016209363A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
AU2014332191B2 (en) Dry powder inhaler
AU2016209363B2 (en) Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat
DK3079744T3 (en) dry powder inhaler
AU2014361087B2 (en) Inhalable medicaments
NZ718315B2 (en) Dry powder inhaler
HK1242605A1 (en) Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat
HK1219444B (zh) 干粉吸入器

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)